Skip to main content

Astrazeneca PLC 6-K, filed Nov 16, 2026

Astrazeneca PLC (AZN)

6-K 2026-11-16 For: 2026-11-16
View Original
Added on November 16, 2026

About this 6-K

Astrazeneca PLC filed this 6-K on November 16, 2026.

AstraZeneca said Baxfendy (baxdrostat) was recommended for EU approval for adults with uncontrolled hypertension. If approved, it would be the EU’s first and only aldosterone synthase inhibitor; two Phase III trials showed reductions of 15.7 mmHg and 16.6 mmHg in systolic blood pressure. AI summary